Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C

Autor: E A Klimova, E Z Burnevich, V P Chulanov, D A Gusev, O O Znoyko, S N Batskikh, S N Kizlo, N A Mamonova, E P Tarkhova, E N Krasavina, M Yu Samsonov, N D Yushchuk

Publikováno v: Терапевтический архив, Vol 91, Iss 8, Pp 67-74 (2019)

Aim. Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C. Materials and methods. The study enrolled adult patients with HCV genotype 1b infection withou

Externí odkaz: https://doaj.org/article/f1aba3c914e347cd9f3228d0e33775ff

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

Autor: D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

Publikováno v: Журнал инфектологии, Vol 8, Iss 3, Pp 122-125 (2016)

In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and r

Externí odkaz: https://doaj.org/article/220e7e7a5aa84b31876844da3c209666

Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C

Autor: Vladimir Chulanov, E.P. Tarkhova, S N Batskikh, N. D. Yushchuk, S N Kizlo, Klimova Ea, E Z Burnevich, M.Yu. Samsonov, O. O. Znoyko, E.N. Krasavina, N A Mamonova, D.A. Gusev

Publikováno v: Терапевтический архив, Vol 91, Iss 8, Pp 67-74 (2019)

Evaluate efficacy and safety of a combination of direct - acting antivirals narlaprevir/ritonavir with daclatasvir in patients with viral hepatitis C.The study enrolled adult patients with HCV genotype 1b infection without demonstrated NS5A resistanc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72855cbd38fd068a689130a0a99086cc
https://doi.org/10.26442/00403660.2019.08.000384

Efficacy and safety of 8-week combination therapy for chronic hepatitis C with protease inhibitor narlaprevir

Autor: V.S. Sukachev, K. V. Zhdanov, E.А. Klimova, S N Batskikh, D.A. Gusev, Vasily Kropochev, E.P. Tarkhova, O. O. Znoyko, N. D. Yushchuk, E.N. Krasavina, M.Yu. Samsonov, Vasily Isakov, Svetlana Kizhlo, K. V. Kozlov

Publikováno v: Infectious diseases: News, Opinions, Training. 9:41-48

Aim of investigation - to estimate efficacy and safety of direct-acting antivirus agents narlaprevir/ritonavir and sofosbuvir in non-cirrhotic patients with chronic hepatitis C Material and methods Treatment naive patients with chronic HCV infection

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22582eb06c638529f4d3b0366b4e0beb
https://doi.org/10.33029/2305-3496-2020-9-3-41-48

Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2

Autor: Yuyong Zhou, Troels K. H. Scheel, Shan Feng, Jens Bukh, Karen A. Gammeltoft, Santseharay Ramirez, Judith M. Gottwein, Long V. Pham, Anna Offersgaard, Andrea Galli, Rui Costa, Carlos Rene Duarte Hernandez, Ulrik Fahnøe

Publikováno v: Antimicrobial Agents and Chemotherapy
Gammeltoft, K A, Zhou, Y, Duarte Hernandez, C R, Galli, A, Offersgaard, A, Costa, R, Pham, L V, Fahnøe, U, Feng, S, Scheel, T K H, Ramirez, S, Bukh, J & Gottwein, J M 2021, ' Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro ', Antimicrobial Agents and Chemotherapy, vol. 65, no. 9, e02680-20 . https://doi.org/10.1128/AAC.02680-20

Antivirals targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could improve treatment of COVID-19. We evaluated the efficacy of clinically relevant hepatitis C virus (HCV) NS3 protease inhibitors (PIs) against SARS-CoV-2 and their

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0fc2c433c7de0ed40ca06a8bfe3c408
https://pubmed.ncbi.nlm.nih.gov/34097489